Support Burnet’s COVID-19 emergency response
COVID-19 represents an unprecedented health, social and economic challenge in Australia and around the world. Support Burnet’s COVID-19 emergency response today.
COVID-19 represents an unprecedented health, social and economic challenge in Australia and around the world. Support Burnet’s COVID-19 emergency response today.
Clinical management, consisting of regular monitoring, and for a minority of people pharmaceutical treatment, reduces hepatitis B disease progression.
Of all people with hepatitis B in Australia, only 13 per cent are clinically managed and of the 5 per cent that do receive pharmaceutical treatment, 20 per cent do not regularly take their medication.
A major gap in the public health response to hepatitis B is to identify the reasons for the reported ‘non-compliance’ of people with hepatitis B to the current model of care or identifying the elements of an effective clinical guideline and future model of care.
2020 – 2021
For any general enquiries relating to this project, please contact:
Senior Research Officer
To achieve better health for vulnerable communities in Australia and internationally by accelerating the translation of research, discovery and evidence into sustainable health solutions.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2020 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung and Wurundjeri people and we offer our respects to the elders past and present.
We recognise and respect the cultural heritage of this land.
